Hematopoietic stem cell (HSC) self renewal and lineage commitment depend on complex interactions with the microenvironment. The ability to maintain or expand HSCs for clinical applications or basic research has been substantially limited because these interactions are not well defined. Recent evidence suggests that HSCs reside in a low-perfusion, reduced-nutrient niche and that nutrient-sensing pathways contribute to HSC homeostasis. Here we report that suppression of the mTOR pathway, an established nutrient sensor, combined with activation of canonical Wnt-b-catenin signaling, allows for the ex vivo maintenance of human and mouse long-term HSCs under cytokine-free conditions. We also show that the combination of two clinically approved medications that together activate Wnt-β-catenin and inhibit mTOR signaling increases the number (but not the proportion) of long-term HSCs in vivo.
HSCs represent a rare population of cells that self renew and gene rate a diversity of mature blood cell types. HSCs serve as a major model system for the study of stem cells and are widely used in HSC transplantation to treat human diseases, including hematopoietic malignancies and bone marrow failure [1] [2] [3] . However, major obstacles remain in the use of HSCs both clinically and as a model system for basic stemcell biology, largely because it has not been possible to maintain functional longterm HSCs (LTHSCs) outside of the complex environment of the hematopoietic niche [4] [5] [6] .
HSCs reside within a lowperfusion environment in the bone marrow with low oxygen tension and reduced nutrient supply [7] [8] [9] [10] . Nutrientsensing systems, such as Lkb1 and mTOR, integrate diverse signals, including mitogenic growth factors, hormones and nutrient availability, and have crucial roles in HSC homeostasis. Loss of Lkb1 (refs. 11-14) or activation of mTOR [15] [16] [17] increases the proliferation of committed progenitors at the expense of HSC maintenance, suggest ing that low nutrient availability is an important feature of the niche that restrains lineage commitment and supports HSC quiescence, self renewal or both.
Isolation and culture of functional LTHSCs has been an elusive goal, as it is not clear what signals provided by the niche are required to maintain HSC quiescence 4, 18 . Recent advances have allowed ex vivo expansion of hematopoietic stem and progenitor cells using cytokine cocktails combined with an array of factors, includ ing aryl hydrocarbon receptor antagonists, Wnt activators, Notch ligands, angiopoietinlike proteins, prostaglandin E 2 , pleiotrophin or glycogen synthase kinase 3 (GSK3) inhibitors in combination with insulin [19] [20] [21] [22] [23] [24] [25] [26] . These approaches are encouraging, but in all cases have required supplementation with a cocktail of hematopoietic cytokines, which may promote lineage commitment at the cost of LTHSC maintenance 4, 18 .
Although the issue is still under debate, Wnt signaling has repeatedly been implicated in HSC self renewal [27] [28] [29] [30] [31] [32] [33] [34] [35] . Wnt signaling is required for normal HSC function, as loss of Wnt3a 34 or βcatenin 35 function or overexpression of the Wnt inhibitor Dkk1 in osteoblasts 36 impairs HSC self renewal, whereas Wnt activation enhances renewal under certain conditions 23, 32, 37, 38 . In contrast, βcatenin deficiency in adult mice [39] [40] [41] does not affect hematopoiesis, and overexpression of an activated form of βcatenin impairs HSC repopulating function 42, 43 .
Several nonexclusive explanations could reconcile these differences. Varying strength of Wnt signaling could result in differing hemato poietic phenotypes, as suggested by an elegant study using an allelic series of Apc mutants, which result in varying degrees of Wnt-β catenin signaling 33 . In addition, Wnt signaling could activate multiple downstream effectors with distinct and potentially contrasting func tions that depend on the mode of activation 25 . For example, inhibi tion of GSK3 activates Wnt signaling and increases the number of immunophenotypic HSCs and hematopoietic progenitor cells (HPCs), but these effects are not sustained, probably because downstream pathways apart from βcatenin signaling are also activated 25, 32 . We have previously found that the increase in the number of immuno phenotypic HSCs associated with GSK3 inhibition requires Wnt-β catenin signaling and that the subsequent loss of LTHSCs occurs because inhibition of GSK3 also activates mTOR 44 .
Thus, we hypothesized that both low nutrient availability and activation of Wnt signaling contribute to HSC maintenance and self renewal. Here we show that human and mouse LTHSCs can be maintained ex vivo in the absence of cytokines, serum or support cells by inhibiting the mTORdependent nutrient sensing pathway and at the same time activating canonical Wnt signaling. Furthermore, the combination of clinically wellestablished inhibitors of GSK3 (lithium) and mTOR (rapamycin) increase the number (but not the proportion) of functional LTHSCs in mice. These observations sup port a role for Wnt signaling and nutrient sensing in HSC mainte nance and identify an approach for culturing HSCs in the absence of exogenous cytokines.
RESULTS

Cytokine-free culture of hematopoietic stem cells
Maintenance of LTHSCs outside of the hematopoietic niche remains a substantial challenge, presumably because conventional culture conditions include a complex mixture of hematopoietic cytokines that promote lineage commitment, lack crucial factors normally sup plied by the niche, or both. A number of protein and smallmolecule factors have been described that enhance culture of HSCs and HPCs, but these are always used in conjunction with multiple cytokines. Our previously published data suggest that GSK3 regulates both the self renewal and lineage commitment of HSCs 44 : inhibition of GSK3 activates Wnt-βcatenin signaling, which promotes self renewal, but GSK3 inhibition also activates mTOR 45 , which promotes lineage commitment and HSC depletion [15] [16] [17] . Thus, the addition of an mTOR inhibitor in the setting of Gsk3 knockdown prevents HSC depletion and maintains Wntdependent HSC expansion in vivo 44 .
As our previous work was in the in vivo setting, it was not clear whether additional factors within the hematopoietic niche contri buted to HSC maintenance in the context of GSK3 and mTOR inhibi tion. To explore the mechanism further, we tested whether inhibition of GSK3 and mTOR would be sufficient for the preservation of HSCs ex vivo under defined culture conditions. We cultured mouse cKit + or Lin -Sca1 + cKit + (LSK) cells, which are enriched for HSCs and HPCs, in serumfree, cytokinefree medium in the presence of the GSK3 inhibitor CHIR99021 plus the mTOR inhibitor rapamycin (C+R) for 7 d ( Fig. 1a and Supplementary Fig. 1 ). We then assessed hematopoietic potential by serial passage in stromal coculture ( Fig. 1b  and Supplementary Fig. 2a -c) and functional HSCs by competi tive repopulation and serial transplantation in lethally irradiated mice ( Fig. 2) .
Coculture on OP9 stromal cells has been used extensively as a sur rogate to test the hematopoietic potential of HSCs and HPCs [46] [47] [48] . Thus, we cultured mouse cKit + cells for 7 d in cytokinefree medium in the presence of C+R or DMSO but without stromal cells and then assessed their hematopoietic potential using the OP9 system. We transferred the cultured cells at three different concentrations into either OP9 or OP9DL1 stromal cocultures (in triplicate). After culturing for 21 d (with two passages), we assessed myeloid and lym phoid differentiation by flow cytometry (FCM) and scored wells as positive if more than 1% of the cells expressed mature lineage markers. All wells (9/9) in the C+Rtreated group gave rise to mature mye loid cells (>54% myeloid cells per well), whereas only 1 well (1/9) of control (DMSOtreated) cells was weakly positive for myeloid line age cells (~4% myeloid cells), and this result was seen only at the highest cell density (2,500 cells) ( Supplementary Fig. 2b ). Myeloid and lymphoid lineage cells were generated from C+Rtreated cKit + cells when cultured on OP9 or OP9DL1 stromal cells, respectively ( Supplementary Fig. 2c ).
We next repeated these experiments with a more purified popula tion of cells. The LSK population is highly enriched for HSCs and HPCs. We sorted LSK cells and cultured them in cytokinefree, serumfree medium with either C+R or DMSO (control). After 7 d, we transferred the cultured LSK cells to stromal cocultures for 21 d and assessed them by FCM as described above. Myeloid and lymphoid lineage cells were generated from the C+Rtreated group but not from the control group when cultured on OP9 or OP9DL1 stromal cells, respectively ( Fig. 1b) .
These data demonstrate that hematopoietic cells that are capable of multilineage hematopoiesis can be maintained in cytokinefree cul ture and raise the possibility that these treated cells contain true HSCs, which, to our knowledge, have not previously been successfully cul tured in cytokinefree conditions. However, stromal coculture systems may allow nonphysiological lineage commitment of hematopoietic precursors and are not a definitive test of HSC function 49 . Bone mar row transplantation remains the gold standard to assess HSC func tion. As a rigorous test of LTHSC function after 7 d in cytokinefree culture, we performed competitive repopulation assays. We cultured cKit + cells in C+R for 1 week and then injected them with competitor cells into lethally irradiated primary recipients. C+Rcultured cells were CD45.1 + to distinguish them from competitors (CD45.2 + ). As lithium is a wellestablished GSK3 inhibitor that is clinically widely used for bipolar disorder, we also tested whether lithium chloride could replace CHIR99021 in cytokinefree culture conditions as a structurally distinct GSK3 inhibitor. Thus, we cultured cKit + cells in lithium chloride plus rapamycin (L+R) and tested them in competi tive repopulation assays in parallel with the C+Rtreated cells. We then harvested bone marrow from the transplant recipient mice after 4 months and assessed chimerism within the LSK Flk2 -CD150 + CD48population by FCM. The degree of chimerism for the C+R (48.4%) and L+R (20.8%) treatment groups was substantially higher than for the DMSO, lithium or rapamycinalone treatment groups. The number of chimericpositive mice, defined by convention as >5% donorderived (CD45.1) cells in either the bone marrow or peripheral blood, was also significantly higher for the C+R (8/9 mice; P < 0.01, oneway analysis of variance) and L+R (7/9; P < 0.05) treatment groups compared to the DMSO control treatment group (3/9) ( Fig. 2a ). C+Rtreated cells also achieved significantly higher chimerism than did cells cultured with CHIR99021 alone (5/9; P < 0.01). Both the L+R and C+R treatment groups showed trilineage reconstitution after 8 and 16 weeks; in these groups we detected donorderived peripheral blood T cells (CD4 + and CD8 + ), B cells (B220 + ), myeloid cells (Gr1 + and Mac1 + (CD11b + )) and erythroid cells (TER119 + ) ( Supplementary  Fig. 3 ). In contrast, there was minimal chimerism in the peripheral blood of DMSOtreated control recipients. We also harvested bone marrow at 4 months from primary recipients of either C+Rtreated or DMSOtreated donor cells and performed transplants directly into secondary recipients. After 4 months, the C+R treatment group achieved substantially higher chimerism in secondary recipients than did the DMSO control treatment group (data not shown). Mouse cKit + cells represent a heterogeneous population. To con firm that the effect of the drugs was directly on HSCs, we cultured sorted LSK cells with DMSO or C+R for 7 d and then transplanted them into lethally irradiated recipients. As with the cultured cKit + cells, we found substantial chimerism in recipients receiving C+R treated cells but not in those receiving DMSOtreated control cells ( Fig. 2b) . As a further test of the longterm selfrenewal capability of HSCs cultured in cytokinefree C+R medium, we performed serial transplantation to secondary and tertiary lethally irradiated hosts. Bone marrow from primary recipients that had been transplanted with C+Rtreated donor cells achieved high chimerism in second ary (mean, 40.5%) and tertiary (mean, 30.3%) recipients, whereas serial transplants from primary recipients of DMSOtreated donor cells had low chimerism in secondary and tertiary recipients (mean, 3.5% and 0.6%, respectively; P < 0.01; Fig. 2c,d) . These results indi cate that HSCs cultured with C+R maintain their potential for long term reconstitution.
To measure the number of HSCs present after culture, we performed a limiting dilution analysis with cKit + cells cultured in C+R or vehicle control. We also used freshly isolated cKit + cells (not cultured) as a positive control. We mixed donor cells at several dilutions (from 1 × 10 3 to 1 × 10 4 cells) with a constant number (2 × 10 5 ) of recipient cells and transplanted them into lethally irradiated recipient mice. After 4 months, we harvested bone marrow, measured the donor chimer ism and calculated the frequency of HSCs ( Fig. 2e) . The frequency of HSCs in C+Rtreated cultures (1/5,700; 95% CI 1/3,140-1/10,326) was similar to that in uncultured cKit + control cells (1/3,540; 95% CI 1/1,991-1/6,300; P = 0.1433), indicating that combined inhibition of GSK3 and mTOR indeed preserves HSCs in cytokinefree culture.
Inhibition of GSK-3 and mTOR maintains human HSCs ex vivo
Human umbilical cord blood (UCB) holds tremendous promise for clinical HSC transplantation (UCBT). The major obstacle to wider application of UCBT is the limited number of cells available in single UCB grafts. Attempts to expand HSCs in UCB using cytokine based cocktails have so far not met with clinical success. Several newer approaches to expand HSCs from UCB have been described recently [19] [20] [21] [22] [23] [24] 26 but have either not been introduced into clinical prac tice or require multiple UCB grafts, and all of these approaches use cocktails of multiple cytokines, which may promote lineage commit ment and reduce LTHSC maintenance. To address whether human HSCs can be maintained in culture without cytokines, we cultured human UCB CD34 + cells in the presence of C+R without serum or cytokines. C+R treatment increased the total cell number up to sevenfold by day 3 (Supplementary Fig. 4) .
To determine the functional HSC frequency of C+Rcultured human cells, we performed xenografts into nonobese diabetic severe combined immunodeficient IL2Rγ null (NSG) mice. At 12 weeks, all mice receiving cells treated with standard cytokines (SCF, Flt3 lig and and Tpo) alone or with C+R alone were engrafted, in contrast to mice receiving cells treated with GSK3 inhibitor alone or vehi cle control, which were not successfully engrafted ( Fig. 3a,b) . C+R cultured human CD34 + cells gave rise to all major lineages ( Fig. 3c) . We also performed secondary transplantation to assess LTHSC func tion. C+Rcultured HSCs achieved efficient longterm engraftment npg comparable to that of uncultured CD34 + cells; in contrast, no sec ondary recipients of HSCs cultured in a standard cytokine cocktail were successfully engrafted ( Fig. 3d) . We also directly compared C+R medium to a serumfree medium containing SCF, Tpo, insulinlike growth factor 2 (IGF2) and fibroblast growth factor 1 (FGF1) (STIF medium), as this cytokine cocktail has been shown to expand mouse and human LTHSCs in ex vivo culture 19, 20, 26 . We cultured human UCB CD34 + cells in serumfree medium for 7 d in the presence of C+R or STIF medium and then performed competitive repopulation assays. HSCs cultured in either C+R or STIF medium engrafted in all primary recipients and the majority of secondary recipients (data not shown). These data indicate that C+R treatment preserves LTHSCs in human UCB in ex vivo, cytokinefree conditions. Furthermore, a lim iting dilution analysis revealed that the frequency of severe combined immunodeficient (SCID) repopulating cells in UCB CD34 + cells cul tured in C+R (1/28,187) was comparable to the frequency in UCB CD34 + cells that were directly transplanted without culture (1/21,901; P = 0.7088), indicating that combined inhibition of GSK3 and mTOR preserves human HSCs in cytokinefree culture ( Table 1) .
Wnt signaling is required for ex vivo HSC maintenance Deficiency or inhibition of Gsk3 leads to stabilization of βcatenin and constitutive activation of Wnt signaling, but the requirement for βcatenin in the hematopoietic response to GSK3 inhibitors has not previously been tested. We first confirmed that GSK3 inhibi tion activates canonical Wnt signaling in cKit + cells using BATgal mice, which carry a lacZ reporter transgene for monitoring canoni cal Wnt signaling 50 . We isolated cKit + cells from the bone marrow of these mice and cultured them in vehicle, CHIR99021 or C+R for 3 d and then assayed the treated cells for βgalactosidase activity by FCM. Either C+R or CHIR99021 alone activated the reporter in LSK Flk2immunophenotypic HSCs and increased expression of the endogenous Wnt target gene Axin2 approximately fourfold in cKit + cells (Supplementary Fig. 5) . These results are similar to previous reports using Wnt or GSK3 inhibitors 32, 33, 38 .
To test whether βcatenin (encoded by Ctnnb1) is required for HSC maintenance in our ex vivo conditions, we crossed mice car rying a conditional Ctnnb1 lossoffunction allele (Ctnnb1 flox/flox ) to mice expressing a tamoxifeninducible Cre allele (cre-ERT2). We treated LSK cells from Ctnnb1 flox/flox ; cre-ERT2 + or Ctnnb1 flox/flox (control) mice with 4hydroxytamoxifen for 2 d to induce deletion of Ctnnb1 (Supplementary Fig. 5c ) and cultured them with C+R or DMSO control for 7 d. We plated the cultured cells on OP9 cells and performed FCM after 3 weeks. C+Rtreated wildtype but not βcatenin-deficient cells gave rise to mature myeloid cells (Fig. 4a) .
To test the requirement for βcatenin in longterm HSC assays in vivo, we used mice carrying the Mx-cre allele to delete Ctnnb1 in hemato poietic cells. We induced Cre in Ctnnb1 flox/flox ; Mx-cre mice with polyinosinepolycytidine (pIpC) (Supplementary Fig. 5d ), harvested cKit + cells from bone marrow, and treated them with C+R or vehicle. Human CD34 + cells from UCB were transplanted directly (uncultured) or cultured for 7 d (with C+R or vehicle) before transplantation. A serial dilution of uncultured or C+R-cultured cells (on the basis of the number of cells present before culture) was injected into NSG hosts. The percentage of human CD45 + cells in the peripheral blood at 12 weeks was measured, and >1% was considered positive for engraftment. The frequency of SCID repopulating cells (SRCs), as calculated with L-Calc software, was not significantly different between uncultured cells and cells cultured in C+R (P = 0.7088). npg After 7 d in culture, we mixed the cells with 3 × 10 5 competitor cells and transplanted them into lethally irradiated recipients. After 4 months, we harvested marrow from these primary recipients and analyzed it by FCM. C+R maintained HSCs in the cKit + cell cultures, and loss of Ctnn1b blocked this effect (Fig. 4b) . These results show that Ctnn1b is required for the ability of C+R treatment to main tain HSCs, and, taken together with previously published observa tions 25, 32 , support a positive role for the Wnt-βcatenin pathway in HSC maintenance when GSK3 is inhibited.
GSK-3 and mTOR inhibition changes the HSC cell-cycle profile
To explore the mechanism by which inhibition of GSK3 and mTOR preserves HSCs and HPCs, we examined the cell cycle and survival status of cultured cKit + cells. We cultured mouse cKit + cells with C+R for 4 d, stained them with antibody to Ki67 and DAPI and then performed FCM to assess cell cycle status in the LSK cell population. Compared to DMSOtreated control cells, more that twice as many C+Rtreated LSK cells were in the G0 phase, indicating an increased percentage of quiescent cells (Fig. 4c) . C+R treatment also led to a small increase in the percentage of cells in the S/G2/M phases, indicat ing a modestly accelerated cellcycle progression. We also analyzed cell death by assessing 7aminoactinomycin D (7AAD) and annexin V staining by FCM. DMSO and C+R treated cells showed similar staining for the most part, except for an increase in early apoptotic cells (annexin V positive and 7AAD negative) in the C+Rtreated group (Fig. 4d) . These results suggest that the maintenance of LSK cells by C+R treatment is not the result of reduced cell death. or littermate control (WT) mice after treatment with pIpC, were cultured in cytokine-free medium with or without C+R for 7 d and were then used in competitive transplants (with 3 × 10 5 fresh bone marrow competitor cells) into lethally irradiated recipients. Chimerism in bone marrow LSK Flk2 -CD150 + CD48cells was determined 4 months after transplantation (n = 3 mice per group). For a and b, depletion of Ctnnb1 was confirmed by western blot ( Supplementary Fig. 5c,d) . 
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GSK-3 and mTOR inhibition increases LT-HSCs in vivo
Both lithium and rapamycin are used extensively in clinical settings, and combining lithium and rapamycin to enhance hematopoietic function could have therapeutic implications. Thus, we performed serial, noncompetitive transplantation using cKit + cells cultured in cytokinefree medium with lithium and rapamycin (L+R). We cultured cKit + cells in L+R or control medium for 7 d and then transplanted them into lethally irradiated recipients. Sixty percent of mice receiv ing L+Rcultured cells (n = 10 mice) survived 4 months or longer, whereas 100% of control mice (receiving cells cultured in DMSO control medium, lithium alone or rapamycin alone) died within 14 d of transplant (Fig. 5a) . All surviving recipients of L+Rtreated cells showed longterm multilineage reconstitution, with >90% of donor derived cells contributing to multiple lineages in the bone marrow ( Fig. 5b) and peripheral blood (data not shown).
In the next experiment, we treated mice with L+R for 2 weeks and compared them to mice receiving vehicle, lithium chloride alone or rapamycin alone. The overall bone marrow cellularity was higher in both the lithium chloride (as observed previously 44 ) and L+R treatment groups compared to vehicle control treatment group or the rapamycin treatment group (Fig. 5c) . The absolute number of immunophenotypic LTHSCs (LSK CD34 -Flk2 -CD150 + CD48 -) also increased in the L+R treatment group compared to the control group (Fig. 5d) . In a competitive repopulation assay, the absolute number of competitive rescue units was increased twofold in bone marrow from mice previously treated with L+R compared to mice receiving vehicle control (5% Tween80 and 5% PEG400) (P < 0.01; Fig. 5e ). Furthermore, the amount of βcatenin protein was increased in whole bone marrow of lithium chloride-and L+Rtreated mice, consistent with activated Wnt signaling under conditions of GSK3 inhibition. The amounts of phosphorylated S6 and 4EBP, which are downstream of mTOR, were increased in lithium chloride-treated mice (Fig. 5f) , and this increase was blocked by rapamycin. These observations show that lithium chloride treatment leads to mTOR activation, consistent with the known ability of GSK3 to inhibit mTOR 44, 45 . Taken together, our data indicate that the combination of two clinically approved drugs increases the number of LTHSCs, as well as the overall number of cells in the bone marrow in vivo.
DISCUSSION
The data presented here show that the combination of activated Wnt and reduced mTOR signaling supports the maintenance of LTHSCs in defined, cytokinefree conditions. These findings also indicate that GSK3 has an essential role in HSC homeostasis as a suppressor of selfrenewal (Wnt) and nutrientsensing (mTOR) pathways. Wntβcatenin signaling promotes stemcell renewal 28 , whereas mTOR activation promotes lineage commitment and stemcell deple tion [15] [16] [17] 51 . Inhibition of GSK3 activates both the Wnt-βcatenin and mTOR pathways in HSCs; concurrent inhibition of mTOR pre vents HSC depletion, allowing ex vivo maintenance (in the absence of growth factors) and an in vivo increase in the number of LTHSCs. The ability to maintain LTHSCs in the absence of exogenous hemato poietic cytokines and increase the number (but not the proportion) of LTHSCs in vivo using two clinically welltolerated medications may have a major impact on stemcell transplantation in hematopoietic malignancies and bone marrow failure.
Difficulty in culturing HSCs has been a major roadblock for both basic research involving HSCs and improving human HSC transplan tation outcomes, as it is difficult to reconstitute the in vivo conditions that maintain or expand HSCs. The use of multiple hematopoietic cytokines, which seem to be essential for the survival of HPCs ex vivo, may also contribute to these difficulties, as these factors probably pro mote lineage specification at the cost of LTHSC function 4, 18 . Thus, an important goal is HSC expansion while limiting or eliminating exposure to lineagepromoting cytokines.
Wnt-βcatenin signaling has been implicated in stemcell self renewal in multiple tissues 28 , but its role in HSC self renewal is not clear. The conflicting reports regarding the role of Wnt-βcatenin signaling in adult HSCs may be explained in part by differential responses to varying levels of Wnt signaling, as has been recently proposed 33 . In addition, Wnt signaling, which inhibits GSK3, can activate both βcatenin and mTOR 45 , which could lead to transient expansion of HSCs that is counteracted by lineage commitment and HSC depletion; in this context, the relative contributions of βcatenin and mTOR activation to HSC fate could also depend on the level of Wnt signaling. Opposing effects of Wnt-βcatenin and mTOR signal ing could also explain the limited response of HSCs to GSK3 inhibi tors when given alone 52 . The ability of C+R treatment to maintain HSCs clearly involves effects on both βcatenin and mTOR, as either βcatenin deficiency or mTOR activity blocks this response. However, additional GSK3-regulated pathways could also have a role.
The use of GSK3 inhibitors to improve hematopoietic function began with lithium before it was known to be a GSK3 inhibitor 52 . Lithium treatment increases the amount of circulating CD34 + cells and increases the production of granulocytes and platelets in most patients 53 . However, clinical trials of lithium met with limited success, possibly because the effects of Wnt activation are mitigated by concur rent activation of mTOR signaling, leading to expansion of progenitor cells and lineage commitment. Consistent with this concept, treatment of bone marrow-transplanted mice with CHIR99021 accelerates the recovery of mature myeloid cells and expands HPCs without increas ing the number of LTHSCs 32 . Similarly, GSK3 inhibitors enhance the progenitor population and hematopoietic reconstitution in mouse primary transplant recipients 23 and preserve longterm-culture initi ating progenitor cells ex vivo when human CD34 + cells are cocultured with stromal cells and cytokines 54 . Furthermore, inhibition of GSK3 combined with insulin expands LTHSCs in culture in the presence of hematopoietic cytokines 25 , suggesting that inhibition of GSK3 combined with additional signals may allow the expansion of HSCs, although the targets downstream of insulin/PI3 kinase signaling were not addressed.
Recent work has shown that HSCs and other somatic stem cells reside in lowperfusion niches [7] [8] [9] [10] and that activation of nutrient sensing pathways enhances lineage commitment at the expense of HSC maintenance. Thus, Lkb1, a multifunctional nutrient sensing kinase, is required to maintain HSC quiescence under reducednutrient conditions, and loss of Lkb1 promotes line age commitment and HSC exhaustion in an mTORindependent manner [11] [12] [13] [14] . However, mutations in genes that inhibit mTOR lead to its activation, mimicking the nutrientreplete state; these muta tions also promote lineage commitment and HSC depletion [15] [16] [17] . These observations, together with the findings reported here, sug gest that reduced nutrient availability, as in a lowperfusion niche or pharmacological inhibition of nutrientsensing pathways, may contribute to the maintenance of LTHSCs. These findings are also consistent with observations that activation of Wnt signaling combined with inhibition of mTOR maintains longterm epidermal stem cells 51 , suggesting that the interplay between Wnt and mTOR might be a general mechanism to regulate the self renewal and differentiation of stem cells.
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In summary, we show that LTHSCs can be maintained ex vivo in the absence of growth factors under conditions of reduced nutrient sens ing (inhibition of mTOR) combined with activation of Wnt signaling, establishing these pathways as crucial for the maintenance of LTHSCs. We also show that a combination of clinically tolerated medications increases the number of LTHSCs and overall bone marrow cellularity in vivo. These studies lay the preclinical groundwork for testing whether outcomes of clinical UCBT can be enhanced through in vivo or ex vivo exposure to GSK3 inhibitors and rapamycin. The clinical application of GSK3 inhibitors should be approached with caution, as activa tion of Wnt signaling has been implicated in malignancies, including colorectal cancers and acute leukemias 55, 56 ; however, lithium has been used to treat bipolar disorder for over 50 years and is not associated with an increased risk of malignancies 57 . Furthermore, the approaches described here involve transient ex vivo or in vivo exposure to GSK3 inhibitors rather than the prolonged activation that is associated with colorectal cancers. Recent studies have also suggested that GSK3 and mTOR regulate T cell memory and that inhibition of GSK3, mTOR or both may enhance the number and functionality of CD8 + memory T cells 58, 59 . Thus, this approach, using agents with already welldefined safety profiles, hold promise for improved hematopoietic recovery and immune reconstitution in UCBT.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Mice. C57BL/6 wildtype (CD45.2 + ), CD45.1 + congenic mice (SJL), Ctnnb1 flox and Mx-cre mice were from The Jackson Laboratory. cre-ERT2 mice were from E. Brown (University of Pennsylvania School of Medicine). Ctnnb1 flox/flox mice were crossed to either Mx-cre or cre-ERT2 mice to generate conditional loss of function mouse lines. Mice were bred inhouse in a pathogenfree mouse facility at the University of Pennsylvania. Transplant recipients were 8 to 10weekold females. Donor mice (used for isolation of cKit + cells in all experiments) were 6 to 8weekold males. Animal experiments were per formed in accordance with guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania.
Cytokine-free HSC culture. HSC culture medium used for serumfree culture of cKit + or LSK cells isolated from mouse bone marrow or CD34 + cells from human UCB consists of XVIVO 15 (BioWhittaker) supplemented with 1% pen icillin and streptomycin (Sigma). CHIR99021 (3 µM) (Stemgent) and rapamycin (5 nM) (Calbiochem) were added a indicated. Bone marrow cells were harvested from C57BL/6 (CD45.2 + ) or SJL (CD45.1 + ) mice and distributed into a single cell suspension by gently drawing through a 22gauge needle three to five times. Red blood cells were lysed in ammonium chloride-potassium (ACK) buffer. Mouse cKit + cells were purified with the Miltenyi MACS cell separation kit. After purification, 50,000 cKit + cells were plated in 1 ml of culture medium per well in a 24well Ubottom plate (Becton Dickinson Company). For experiments using sorted LSK cells, sorted cells were distributed into 96well Ubottom plates at 1,000 cells per well with 200 µl medium. Onehalf volume of medium was replaced every other day. After 7 d, the total culture product was harvested, and cells were washed and transplanted into lethally irradiated mice.
FCM and isolation of HSCs. Bone marrow cells were flushed from the long bones (tibias and femurs) of mice with HBSS without calcium or magnesium. For detection of LSK cells, whole bone marrow cells were incubated with biotin conjugated monoclonal antibodies to lineage markers, including B220 (6B2), CD4 (GK1.5), CD8 (536.7), Gr1 (8C5), Mac1 (M1/70), Ter119 (Ter119) and interleukin7 receptor (IL7R) (A7R34), PerCP Cy5.5conjugated antibody to Sca1 (Ly6A/E; D7) and allophycocyanin (APC)Alexa Fluor 750-conjugated antibody to cKit (ACK2). Flk2, CD34, CD150 and CD48 were measured with the following antibodies: phycoerythrin (PE)conjugated antibody to Flk2 (Ly72/ clone #A2F10), Alexa Fluor 647-conjugated antibody to CD34 (RAM34), PE Cy5conjugated antibody to CD48 (HM481) and PE Cy7conjugated anti body to CD150 (TC1512F 12.2). All antibodies were purchased from eBio science except for antibodies to CD150 and CD48, which were purchased from Biolegend. Biotinconjugated lineage markers were detected using streptavi dinconjugated PE-Texas Red. Antibodies to B220, CD4, CD8, Gr1, Mac1 and interleukin7 receptor (IL7R) were diluted 1:550. Antibodies to Sca1, cKit, CD150, CD48 and Flk2 were diluted 1:80. Antibodies to Ter119 and GR1 were diluted 1:275. Antibody to CD34 was diluted 1:35. Nonviable cells were excluded using the viability dye DAPI (1 g ml -1 ). Cells were sorted with a FACSAria (Becton Dickinson) automated cell sorter. Analyses were performed on LSR II, FACSCanto or FACSCalibur flow cytometers (Becton Dickinson). Data were analyzed using FlowJo software (Tree Star).
Wnt reporter assay by flow cytometry.
Mouse cKit + cells were harvested from the BATgal Wnt reporter mouse line (provided by S. Piccolo, University of Padova). The FluoReporter lacZ Flow Cytometry Kit (Invitrogen) was used for quantifying βgalactosidase activity by assessing fluorescein diVgalactoside staining in single cells using flow cytometry.
OP9 cell cultures. OP9MigR1 (OP9) and OP9DL1 cells (provided by A. Bhandoola, University of Pennsylvania School of Medicine) were used as described 60 . Mouse cKit + or LSK progenitors were seeded into 12well plates containing a confluent stromal monolayer of OP9 or OP9DL1 cells, which had been γirradiated ( 137 Cs) at a dose of 30 Gy. The cytokines mouse Flt3 ligand (5 ng ml -1 ) and mouse IL7 (5-10 ng ml -1 ) (Peprotech) were added to the coculture. The cells were passaged every 7 d to freshly irradiated OP9 or OP9DL1 stromal cells.
Long-term repopulation assays. For longterm noncompetitive repopula tion, adult recipient mice were irradiated with a cesium137 irradiator in two equal doses of 500 rads separated by at least 2 h. Cells were injected into the retroorbital venous sinus of anesthetized recipients. Beginning 4 weeks after transplantation and continuing for at least 16 weeks, blood was collected from the tail veins of recipient mice and analyzed by FCM for the lineage markers B220 (6B2), Mac1 (M1/70), CD4 (L3T4), CD8 (Ly3) and Gr1 (8C5) to monitor engraftment by FCM. For longterm competitive repopulation, CD45.1 + cKit + cells from C+R or DMSOtreated cultures were transplanted into lethally irradi ated C57BL/6 recipients together with 3 × 10 5 competitor B6 bone marrow cells (CD45.2 + ). In limiting dilution analyses, uncultured cKit + cells or cells cultured in C+R or DMSO control medium for 1 week were injected together with 3 × 10 5 competitor cells into lethally irradiated primary recipients. Beginning 4 weeks after transplantation and continuing for up to 16 weeks, peripheral blood was collected and analyzed by FCM as described above to monitor engraft ment. Bone marrow was harvested and analyzed 16 weeks after transplantation. In serial transplantations, the bone marrow was harvested from primary recipients after 4 months, and 20 × 10 6 bone marrow cells were transplanted into each lethally irradiated secondary recipient.
Xenotransplant assays. Gender balanced severe combined immunodeficient IL2Rγ null (NSG) mice (provided by the Stem Cell and Xenograft Core Facility at the University of Pennsylvania School of Medicine) were used in this study. Adult recipients were irradiated with a cesium137 irradiator in two equal doses of 400 rads separated by at least 2 h. Cells were injected into the retro orbital venous sinus of anesthetized recipients. In serial transplantation experi ments, bone marrow was harvested from primary recipients after 4 months, and 90% of the total bone marrow cells (from four tibias, four femurs and two hips) was transplanted into each sublethally irradiated secondary recipient mouse (NSG).
Administration of pIpC, rapamycin and lithium chloride. pIpC (Sigma) was resuspended in Dulbecco's PBS at 2 mg ml -1 . Mice received 25 mg of pIpC per kg body weight every other day for 2 weeks. Rapamycin (LC Laboratories) was dissolved in absolute ethanol at 10 mg ml -1 and diluted in 5% Tween80 (Sigma) and 5% PEG400 (Hampton Research) before injection and was administered by intraperitoneal injection at 4 mg per kg body weight rapamycin in 200 µl total volume per injection every other day for 2-3 weeks. For lithium treatment, mice were fed 0.2% (w/w) lithium chloride (LiCl) mouse chow (Harlan Teklad) ad libitum for 3 d followed by 0.4% (w/w) LiCl mouse chow for the duration of the experiment. All mice had access to supplemental 450 mM sodium chloride drinking solution.
Statistical methods. Pairwise comparisons were analyzed using a twotailed Student's t test, and results were considered significant when P < 0.05. Data involving multiple samples (as in Fig. 2a ) were analyzed with oneway analysis of variance followed by Dunn's post hoc analysis when a significant difference was found among the groups. 
